Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)
ID: 335602Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/335602

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-21-330.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research" through a Cooperative Agreement mechanism. This initiative aims to advance research in cancer etiology and early detection biomarkers by utilizing the unique biorepository resources from the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial, which includes high-quality pre-diagnostic blood samples and associated demographic and clinical data. Eligible applicants include a diverse range of institutions such as higher education institutions, nonprofits, and various government agencies, with project periods extending up to five years and budgets reflecting actual needs. Applications must be submitted by October 11, 2024, and further inquiries can be directed to the NIH OER Webmaster at OERWebmaster03@od.nih.gov. For more details, interested parties can refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-21-330.html.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-21-330-Full-Announcement.html
    PAR-21-330.html
    The Department of Health and Human Services, through the National Cancer Institute (NCI), issued a Funding Opportunity Announcement (FOA) aimed at advancing cancer research via the Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Biorepository. This initiative encourages applications utilizing pre-diagnostic biospecimens to explore cancer etiology and early detection biomarkers. The PLCO Biorepository provides high-quality blood samples and associated demographic and clinical data from a diverse participant pool. Research proposals must incorporate these biospecimens, focusing on novel cancer risk biomarkers or non-cancer aging-related outcomes, and should leverage the unique characteristics of the PLCO data. Eligible applicants include higher education institutions, nonprofits, and various government agencies, with project periods extending up to five years and budgets reflecting actual needs. The application is non-clinical trial based, and support from NCI staff is anticipated. Applications must comply with specific submission requirements and timelines, ensuring adherence to all NIH policies. This FOA offers significant resources for advancing cancer research through rigorous scientific investigation utilizing the unique PLCO dataset.
    Similar Opportunities
    Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)." This initiative aims to establish population-based cancer epidemiology cohorts to address critical knowledge gaps in cancer etiology and survivorship, particularly focusing on engaging diverse and underserved populations. The project will support methodological work necessary for cohort development, emphasizing community engagement and the validation of cancer outcomes linked to population-based registries. Interested applicants, including educational institutions, nonprofits, and local governments, must submit their proposals by February 28, 2025, and can find additional details at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional)." This initiative aims to support innovative research projects that integrate advanced imaging techniques, biomarkers, and digital pathomics to enhance the early detection of aggressive cancers and precancerous lesions, thereby improving diagnostic accuracy and reducing overdiagnosis. The program emphasizes the importance of multidisciplinary collaboration in cancer research, particularly focusing on high-risk cancers such as pancreatic and lung cancers. Interested applicants, including higher education institutions, nonprofits, and government entities, must submit their proposals by September 7, 2025, and can find additional information and application details at the NIH website or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating well-planned clinical trials that enhance cancer prevention, treatment, and survivorship care. This funding opportunity seeks to address critical gaps in trial planning by acquiring essential data for finalizing protocols, including feasibility assessments and stakeholder engagement strategies. The program is particularly significant for improving cancer-related health behaviors and outcomes, with grants available up to $600,000 for trials including pilot studies, over a maximum of three years. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by September 7, 2025, and can direct inquiries to OERWebmaster03@od.nih.gov for further information.
    Cancer Prevention and Control Clinical Trials Planning Grant Program (U34 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the Cancer Prevention and Control Clinical Trials Planning Grant Program (U34), aimed at facilitating the planning of clinical trials that enhance cancer prevention, intervention, and survivor care. This program seeks to address critical information gaps that hinder effective trial protocols, including population characteristics and operational risks, by requiring applicants to submit a Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity in research teams and participant recruitment. With funding of up to $225,000 per year available for planning initiatives, eligible organizations include higher education institutions, non-profits, and tribal governments, with a project period of up to three years. Interested applicants should note the submission deadline of January 25, 2025, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Research Resource for Human Organs and Tissues (U42 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research Resource for Human Organs and Tissues" through a cooperative agreement mechanism (U42), aimed at supporting a program that provides and facilitates the availability of human tissues and organs for biomedical research. The initiative seeks to enhance the procurement, preservation, and distribution of diverse biospecimens, both normal and diseased, to aid researchers in understanding various diseases and addressing public health priorities. Applicants must demonstrate a proven track record in managing a human tissue and organ research resource, with direct costs capped at $720,000 over a potential five-year project period. The application period opens on December 24, 2024, with a submission deadline of September 25, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities" (R01, Clinical Trial Required). This initiative aims to solicit applications for projects that identify and address barriers to cancer screening and preventive services, particularly in underserved populations, through multi-level interventions involving patients, clinicians, healthcare settings, and community partners. The focus is on developing evidence-based strategies to improve cancer outcomes for groups such as Black Americans, Hispanics, and Native Americans, emphasizing health equity and structured research methodologies. Interested applicants can find more details and submit proposals by January 7, 2027, with the first application due date being October 5, 2023. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov, and further information is available at NIH Grants.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Assay Validation of High Quality Markers for Clinical Studies in Cancer" through a cooperative agreement mechanism (UH2/UH3). This initiative aims to support the validation of molecular, cellular, and imaging biomarkers essential for cancer detection, diagnosis, prognosis, and treatment response monitoring, with a focus on both analytical and clinical validation phases. The funding is intended for projects that demonstrate a working assay on human samples and justify its clinical relevance, fostering multi-disciplinary collaborations among scientific investigators, oncologists, and clinical laboratory scientists. Interested applicants should note that the application deadline is October 14, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. More details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-25-074.html.
    Population Genomic Screening in Primary Care Sequencing Center (U01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for the "Population Genomic Screening in Primary Care Sequencing Center (U01 - Clinical Trial Optional)" grant, aimed at establishing a Sequencing Center to support a new population screening network. This initiative focuses on providing genomic sequencing services for 20,000 study participants, particularly targeting actionable conditions identified by the CDC, such as hereditary breast and ovarian cancer and Lynch syndrome, while ensuring inclusive recruitment from health disparity populations. The program emphasizes collaboration with community stakeholders and primary care providers to enhance genomic testing and follow-up care, ultimately aiming to integrate genomic medicine into primary care and address health disparities. Interested applicants should note that the total budget for the first year is $600,000, with escalating costs for subsequent years, and the application deadline is December 2, 2024. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the opportunity announcement at https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-24-023.html.
    Population Genomic Screening in Primary Care Coordinating Center(U01 -Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is soliciting applications for a Cooperative Agreement to establish a Coordinating Center focused on population genomic screening in primary care settings. This initiative aims to evaluate and implement screening for 4-7 common genomic conditions, emphasizing community engagement and the integration of healthcare equity, particularly for underserved populations. The program, managed by the National Human Genome Research Institute (NHGRI), seeks to develop frameworks for effective genomic screening practices while adhering to NIH’s data sharing and clinical trial registration policies. Interested applicants can access the full announcement at NIH Grants, with a funding commitment of $5.75 million over five years and an application deadline of December 2, 2024. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.